David Goodman-Meza and Raphael J. Landovitz are with Division of Infectious Diseases, David Geffen School of Medicine at University of California Los Angeles (UCLA). Raphael J. Landovitz is also with Center for Clinical AIDS Research and Education, Los Angeles. Maria Elena Medina-Mora is with Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico. Carlos Magis-Rodríguez is with National Center for the Prevention and Control of HIV and AIDS, Mexico City. Steve Shoptaw is with Department of Family Medicine, David Geffen School of Medicine at UCLA. Dan Werb is with Department of Medicine, University of California San Diego, La Jolla.
Am J Public Health. 2019 Jan;109(1):73-82. doi: 10.2105/AJPH.2018.304767. Epub 2018 Nov 29.
In North America, opioid use and its harms have increased in the United States and Canada over the past 2 decades. However, Mexico has yet to document patterns suggesting a higher level of opioid use or attendant harms.Historically, Mexico has been a country with low-level use of opioids, although heroin use has been documented. Low-level opioid use is likely attributable to structural, cultural, and individual factors. However, a range of dynamic factors may be converging to increase the use of opioids: legislative changes to opioid prescribing, national health insurance coverage of opioids, pressure from the pharmaceutical industry, changing demographics and disease burden, forced migration and its trauma, and an increase in the production and trafficking of heroin. In addition, harm-reduction services are scarce.Mexico may transition from a country of low opioid use to high opioid use but has the opportunity to respond effectively through a combination of targeted public health surveillance of high-risk groups, preparation of appropriate infrastructure to support evidence-based treatment, and interventions and policies to avoid a widespread opioid use epidemic.
在北美,过去 20 年来,美国和加拿大的阿片类药物使用及其危害不断增加。然而,墨西哥尚未记录表明阿片类药物使用水平更高或伴随危害更大的模式。从历史上看,墨西哥一直是一个阿片类药物使用水平较低的国家,尽管有记录表明存在海洛因使用情况。低水平的阿片类药物使用可能归因于结构性、文化性和个体性因素。然而,一系列动态因素可能正在汇聚,导致阿片类药物使用增加:阿片类药物处方的立法改革、国家医疗保险覆盖阿片类药物、制药行业的压力、人口结构和疾病负担的变化、被迫迁移及其创伤,以及海洛因产量和贩运的增加。此外,减少伤害服务稀缺。墨西哥可能会从一个阿片类药物使用水平较低的国家过渡到一个阿片类药物使用水平较高的国家,但有机会通过对高风险群体进行有针对性的公共卫生监测、准备适当的基础设施以支持基于证据的治疗,以及采取干预措施和政策来避免广泛的阿片类药物使用流行,从而做出有效应对。